Hot Heal Care Stocks To Watch For 2018

What happened

Shares of Atwood Oceanics (NYSE:ATW) are bounding higher on Wednesday and were up more than 13% by 3:00 p.m. EDT. There wasn’t any news to drive the stock higher today. Instead, it appears that investors finally decided they like the company’s messy fiscal second-quarter report.

So what

Atwood Oceanics reported a mixed quarter on Monday night because of several one-time items. On the positive side, the company benefited from a one-time $48.1 million payment after a client chose to revert a contract back to the original term. Further, it recorded an $8.4 million gain on the extinguishment of debt. That said, the company also took a $59 million impairment charge after it wrote down a rig to its salvage value and subsequently sold that vessel for recycling.

Image source: Getty Images.

While that report was neutral at best, there were a few things CEO Robert Saltiel said on the subsequent conference call worth noting. First, he pointed out that one of its clients,Kosmos Energy (NYSE:KOS), just made another offshore gas discovery in Senegal. Because of Kosmos Energy’s success, Atwood was in discussions to extend its current contract. Meanwhile, Saltiel noted that Atwood was working on several opportunities for new rig contracts, and he was “hopeful” that the company would win some of these deals. That optimism appears to be one of the fuels of today’s rally.

Hot Heal Care Stocks To Watch For 2018: CyberArk Software Ltd.(CYBR)

Advisors’ Opinion:

  • [By Joe Tenebruso]

    CyberArk Software (NASDAQ:CYBR) reported fourth-quarter financial results on Feb. 9. The Israeli cybersecurity specialist continues to win new business for its “privileged account” security solutions, which help to protect against cyberattacks that use insider privileges to penetrate network perimeters and assault the most sensitive areas of an enterprise’s IT infrastructure.

  • [By Lisa Levin]

    Some of the stocks that may grab investor focus today are:

    Wall Street expects Citigroup Inc (NYSE: C) to report quarterly earnings at $1.26 per share on revenue of $17.71 billion before the opening bell. Citigroup shares rose 0.30 percent to $67.22 in after-hours trading.
    Analysts are expecting JPMorgan Chase & Co. (NYSE: JPM) to have earned $1.65 per share on revenue of $25.61 billion in the latest quarter. JPMorgan will release earnings before the markets open. JPMorgan shares gained 0.48 percent to $93.55 in after-hours trading.
    Cyberark Software Ltd (NASDAQ: CYBR) lowered its guidance for the second quarter. The company now expects total revenue of $57.0 million to $57.5 million, versus earlier guidance of $61.0 million to $62.0 million. Cyberark shares dipped 17.65 percent to $42.00 in the after-hours trading session.
    Before the opening bell, First Republic Bank (NYSE: FRC) is projected to report quarterly earnings at $1.1 per share on revenue of $675.70 million. First Republic Bank shares dropped 0.80 percent to close at $101.35 on Thursday.

    Find out what's going on in today's market and bring any questions you have to Benzinga's PreMarket Prep.

  • [By ]

    RB: I thought wed be up more than we are on cybersecurity plays. We have 25% gains on recommendations like Palo Alto Networks (NYSE: PANW). Were off a few percentage points on CyberArk Software (NASDAQ: CYBR).

Hot Heal Care Stocks To Watch For 2018: GlaxoSmithKline PLC(GSK)

Advisors’ Opinion:

  • [By Keith Speights]

    There are several choices for investing in HIV drug stocks. Three of the best options for long-term investors are Gilead Sciences (NASDAQ:GILD), GlaxoSmithKline (NYSE:GSK), and Merck (NYSE:MRK). Here’s why these HIV drug stocks could be solid picks in 2017.

  • [By Keith Speights]

    Gilead’s primary rival in the HIV market is Viiv Healthcare, which is majority-owned byGlaxoSmithKline (NYSE:GSK).The company recently announced positive results from a late-stage clinical study of its HIV drug Tivicay combined with Johnson & Johnson’s Edurant.

  • [By Todd Campbell]

    Also, like in hepatitis C, competitors are attempting to win away market share. For example,ViiV Healthcare, a joint venture spearheaded by GlaxoSmithKline(NYSE:GSK), is actively pursuing new HIV therapies that could make it more difficult for Gilead Sciences to maintain its market share dominance. In December, ViiV announced that a single tablet, two-drug combination that includes Johnson & Johnson’s Edurant met its primary endpoint in phase 3 studies. A filing for FDA approval is slated for this year.

  • [By Sean Williams]

    Third, in late March, Mylan announced that the Food and Drug Administration had rejected its application to market a generic version of GlaxoSmithKline’s (NYSE:GSK) blockbuster asthma and COPD inhalable drug, Advair. GlaxoSmithKline’s Advair lost patent protection more than six years ago, but only within the past couple of years did the FDA lay out a course for generic drug producers to follow in order to get a generic version of the drug approved. Meanwhile, Glaxo still enjoys blockbuster sales of Advair as generic versions of the drug have yet to hit the market.

  • [By WWW.MONEYSHOW.COM]

    Two of our top holdings, GlaxoSmithKline (GSK) and Merck (MRK) have seen substantial improvement in earnings as new drugs start to build market share. Glaxo and Merck offer dividend yields of 4.71% and 3.08%, respectively.

Hot Heal Care Stocks To Watch For 2018: Pinnacle Bankshares Corporation (PPBN)

Advisors’ Opinion:

  • [By WWW.MONEYSHOW.COM]

    Pinnacle Bankshares (PPBN) is a 100 + year old bank in Virginia; it is also growing like crazy, loan quality also very strong, great market share and a wealthy market area.

  • [By SEEKINGALPHA.COM]

    A community bank that I know you haven’t heard of is Pinnacle Bankshares (OTCQX:PPBN). Pinnacle Bankshares is your typical community bank. The bank’s assets are almost at $400 million, the market cap is trending around $30 million and the bank has a handful of locations in the Virginia area. Even though the bank is relatively unheard of, there is quite a lot to like as an investor.

Leave a Reply

Your email address will not be published. Required fields are marked *